KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Asset Utilization Ratio (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Asset Utilization Ratio for 15 consecutive years, with 0.59 as the latest value for Q4 2025.

  • Quarterly Asset Utilization Ratio rose 21.18% to 0.59 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.59 through Dec 2025, up 21.18% year-over-year, with the annual reading at 0.61 for FY2025, 13.81% up from the prior year.
  • Asset Utilization Ratio for Q4 2025 was 0.59 at Halozyme Therapeutics, up from 0.58 in the prior quarter.
  • The five-year high for Asset Utilization Ratio was 0.59 in Q4 2025, with the low at 0.32 in Q3 2022.
  • Average Asset Utilization Ratio over 5 years is 0.45, with a median of 0.43 recorded in 2021.
  • The sharpest move saw Asset Utilization Ratio skyrocketed 37.88% in 2021, then decreased 23.94% in 2022.
  • Over 5 years, Asset Utilization Ratio stood at 0.39 in 2021, then dropped by 8.0% to 0.36 in 2022, then rose by 28.4% to 0.46 in 2023, then grew by 6.17% to 0.49 in 2024, then rose by 21.18% to 0.59 in 2025.
  • According to Business Quant data, Asset Utilization Ratio over the past three periods came in at 0.59, 0.58, and 0.55 for Q4 2025, Q3 2025, and Q2 2025 respectively.